UNSPSC 51282901: Cinoxacin

This classification denotes a quinolone antibiotic with the molecular formula C12H10N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LMK22VUH23, chemically known as 1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-carboxylic acid but generally known as cinoxacin, which bears US NIH Compound Identifier 2762. European Medicines Agency schedules Cinoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06309MIG.

UNSPSC 51282901 Cinoxacin is a Commodity code that nominally covers a specific antibiotic pharmaceutical product, but recent state and local solicitations show little activity directly aligned with cinoxacin itself. The most recent opportunities tagged under this code involve procurement of other pharmaceutical products—notably antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and naloxone—through health departments and county agencies. The actual buying under this code appears to reflect broader pharmaceutical supply and emergency medical response needs rather than cinoxacin-specific demand. State and local issuing bodies using this code span state health departments and county health agencies; the Illinois Department of Public Health and Seminole County, Florida are the identified recent buyers.

Activity is geographically sparse, with recent opportunities appearing only in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392, IFB process, $2.999 million over three years) for supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets with 12-month initial term and renewal options. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, posted June 30, 2026) for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the county community health building and a two-year initial term plus one-year renewal option. This code shows minimal recent activity overall, and the opportunities present do not align cleanly with cinoxacin procurement—a signal to confirm whether the code is correctly applied to your target markets or whether activity under it has shifted to other pharmaceutical categories.